This is a working overview of Angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
In geology, hotspots (or hot spots) are volcanic locales thought to be fed by underlying mantle that is anomalously hot compared with the surrounding mantle. Examples include the Hawaii, Iceland, and Yellowstone hotspots. A hotspot's position on the Earth's surface is independent of tectonic plate boundaries, and so hotspots may create a chain of volcanoes as the plates move above them. There are two hypotheses that attempt to explain their origins. One suggests that hotspots are due to mantle plumes that rise as thermal diapirs from the core–mantle boundary. The alternative plate theory is that the mantle source beneath a hotspot is not anomalously hot, rather the crust above is unusually weak or thin, so that lithospheric extension permits the passive rising of melt from shallow depths.
Etazocine (NIH-7856) is an opioid analgesic of the benzomorphan family which was never marketed. It acts as a partial agonist of the opioid receptors, with mixed agonist and antagonist effects. In animal studies, it was shown to induce analgesia, dependency, and respiratory depression, with overall effects similar to those of morphine, but with substantially reduced potency in comparison.
The first automated insulin delivery system was known as the Biostator. Currently available AID systems fall into three broad classes based on their capabilities. The first systems released can only halt insulin delivery (predictive low glucose suspend) in response to already low or predicted low glucose. Hybrid Closed Loop systems can modulate delivery both up and down, although users still initiate insulin doses (boluses) for meals and typically "announce" or enter meal information. Fully Closed Loops require no manual insulin delivery actions or announcement for meals. A step forward from threshold suspend systems, predictive low glucose suspend (PLGS) systems use a mathematical model to extrapolate predicted future blood sugar levels based on recent past readings from a CGM. This allows the system to reduce or halt insulin delivery prior to a predicted hypoglycemic event.
Electron emission (β−) to 40Ca with a decay energy of 1.31 MeV at 89.6% probability Electron capture (EC) to 40Ar* followed by a gamma decay emitting a photon with an energy of 1.46 MeV at 10.3% probability Direct electron capture (EC) to the ground state of 40Ar at 0.1% probability Positron emission (β+) to 40Ar at 0.001% probability Both forms of the electron capture decay release further photons, when electrons from the outer shells fall into the inner shells to replace the electron taken from there. The total energy for the decay to argon is 1.51 MeV. The EC decay of 40K explains the large abundance of argon (nearly 1%) in the Earth's atmosphere, as well as prevalence of 40Ar over other isotopes.
== Mechanism == The underlying reason for its occurrence is unclear, though the syndrome appears similar to withdrawal from other psychotropic drugs such as benzodiazepines. For SSRIs, a tapered discontinuation results in less severe symptoms. There is also evidence that antidepressant discontinuation syndrome may be related to the biological half-life of both SSRIs and antidepressants in general. Antidepressants with a lower half-life, such as paroxetine, duloxetine, and venlafaxine, have been implicated in higher incidences of withdrawal symptoms and more severe withdrawal symptoms. The opposite association has been observed in antidepressants with relatively longer half lives, such as fluoxetine. With SSRIs, duration of treatment does not appear associated with the severity of withdrawal symptoms. One hypothesis is that after the antidepressant is discontinued, there is a temporary (but in some cases long-lasting) deficiency in the brain of one or more essential neurotransmitters that regulate mood, such as serotonin, dopamine, norepinephrine, and GABA (gamma-aminobutyric acid), and since neurotransmitters are an interrelated system, dysregulation of one affects the others. There may be a link between lower 5-hydroxytryptamine (5-HT, i.e. serotonin) receptor availability and symptoms of antidepressant discontinuation syndrome. Among antidepressants analyzed by Gastaldon et al. (2022), lofepramine, vortioxetine, mianserin, agomelatine, and esketamine are not associated with significantly disproportionate reporting of withdrawal syndrome.
Sources: en.wikipedia.org
Lipases are serine hydrolases, i.e. they function by transesterification generating an acyl serine intermediate. Most lipases act at a specific position on the glycerol backbone of a lipid substrate (A1, A2 or A3). For example, human pancreatic lipase (HPL), converts triglyceride substrates found in ingested oils to monoglycerides and two fatty acids. A diverse array of genetically distinct lipase enzymes are found in nature, and they represent several types of protein folds and catalytic mechanisms. However, most are built on an alpha/beta hydrolase fold and employ a chymotrypsin-like hydrolysis mechanism using a catalytic triad consisting of a serine nucleophile, a histidine base, and an acid residue, usually aspartic acid.
== Health claims == By the early 2010s, "bone broth" had become a popular health food trend, due to the resurgence in popularity of dietary fat over sugar, and interest in "functional foods" to which "culinary medicinals" such as turmeric and ginger could be added. Bone broth bars, bone broth home delivery services, bone broth carts, and bone broth freezer packs grew in popularity in the United States. The fad was heightened by the 2014 book Nourishing Broth, in which authors Sally Fallon Morell and Kaayla T. Daniel claim that the broth's nutrient density has a variety of health effects. There is no scientific evidence to support many of the claims made for bone broth.
=== Pregnancy === Dexamethasone may be given to women at risk of delivering prematurely to promote maturation of the fetus's lungs. This administration, given from one day to one week before delivery, has been associated with low birth weight, although not with increased rates of neonatal death. Dexamethasone has also been used during pregnancy as an off-label prenatal treatment for the symptoms of congenital adrenal hyperplasia (CAH) in female babies. CAH causes a variety of physical abnormalities, notably ambiguous genitalia. Early prenatal CAH treatment has been shown to reduce some CAH symptoms, but it does not treat the underlying congenital disorder. This use is controversial: it is inadequately studied, only around one in ten of the fetuses of women treated are at risk of the condition, and serious adverse events have been documented. Experimental use of dexamethasone in pregnancy for fetal CAH treatment was discontinued in Sweden when one in five cases had adverse events. A small clinical trial found long-term effects on verbal working memory among the small group of children treated prenatally, but the small number of test subjects means the study cannot be considered definitive.
== Distribution == This nudibranch was described from San Diego, California, United States. It has been reported from Northern California, to Punta Eugenia, Mexico. Its distribution overlaps with Hermissenda crassicornis in Northern California and this latter species is found north to Alaska. These two species were routinely treated as a single species during the last 90 years. The species has also been observed in Bahia de los Angeles, Gulf of California.
Sources: en.wikipedia.org
Superconductivity in the cuprates is considered unconventional and is not explained by BCS theory. Possible pairing mechanisms for cuprate superconductivity continue to be the subject of considerable debate and further research. Similarities between the low-temperature antiferromagnetic state in undoped materials and the low-temperature superconducting state that emerges upon doping, primarily the dx2−y2 orbital state of the Cu2+ ions, suggest that electron-phonon coupling is less relevant in cuprates. Recent work on the Fermi surface has shown that nesting occurs at four points in the antiferromagnetic Brillouin zone where spin waves exist and that the superconducting energy gap is larger at these points. The weak isotope effects observed for most cuprates contrast with conventional superconductors that are well described by BCS theory. In 1987, Philip Anderson proposed that superexchange could act as a high-temperature superconductor pairing mechanism. In 2016, Chinese physicists found a correlation between a cuprate's critical temperature and the size of the charge transfer gap in that cuprate, providing support for the superexchange hypothesis. A 2022 study found that the varying density of actual Cooper pairs in a bismuth strontium calcium copper oxide superconductor matched with numerical predictions based on superexchange. But so far there is no consensus on the mechanism, and the search for an explanation continues. Similarities and differences in the properties of hole-doped and electron-doped cuprates:
== External links == The Bülow case at www.crimelibrary.com Clarendon Court Mansion, Bülow's former home Obituary in the Star Gazette National Center for Victims of Crime (formerly the Sunny Von Bulow National Victim Advocacy Center)
=== Aldosterone feedback === Feedback by aldosterone concentration itself is of a nonmorphological character (that is, other than changes in the cells' number or structure) and is poor, so the electrolyte feedbacks predominate, short term.
== Role in obesity == AgRP induces obesity by chronic antagonism of the MC4-R. Overexpression of AgRP in transgenic mice (or intracerebroventricular injection) causes hyperphagia and obesity, whilst AgRP plasma levels have been found to be elevated in obese human males. Understanding the role AgRP plays in weight gain may assist in developing pharmaceutical models for treating obesity. AgRP mRNA levels have been found to be down regulated following an acute stressful event. Studies suggest that systems involved in the regulation of stress response and of energy balance are highly integrated. Loss or gain of AgRP function may result in inadequate adaptive behavioural responses to environmental events, such as stress, and have potential to contribute to the development of eating disorders. It has been shown that polymorphisms in the AgRP gene have been linked with anorexia nervosa as well as obesity. Some studies suggest that inadequate signalling of AgRP during stress may result in binge eating. Starvation-induced hypothalamic autophagy generates free fatty acids, which in turn regulate neuronal AgRP levels.
=== Wedge === The term wedge is used in the New York counties of Dutchess, Putnam, and Westchester, as well as the Connecticut county of Fairfield–four counties directly north of New York City. Some base the name wedge on a diagonal cut in the middle of the sandwich, creating two halves or "wedges", or a "wedge" cut out of the top half of the bread with the fillings "wedged" in between, or a sandwich that is served between two "wedges" of bread. It has been said that wedge is short for "sandwich", with the name having originated from an Italian deli owner located in Yonkers, who got tired of saying the whole word.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.